약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 5.

Table. 5.

Causal inference approach of the association of statin use with cirrhosis and hepatocellular carcinoma according to statin subclass

Outcome Statin type (N) IPW analysis Superlearning TMLE
Marginal OR 95% CI Marginal OR 95% CI
By statin type
Cirrhosis atorvastatin ( 11,867) 0.62** 0.55-0.69 0.58** 0.50-0.65
rosuvastatin (2,482 ) 0.60** 0.43-0.77 0.59** 0.48-0.70
simvastatin ( 8,353) 0.66** 0.57-0.76 0.63** 0.52-0.71
lovastatin (499 ) 0.64* 0.31-0.98 0.71** 0.59-0.83
pravastatin (2,402) 0.89 0.69-1.09 0.83 0.67-1.0
fluvastatin (710) 1.19 0.64-1.74 0.96 0.82-1.12
pitavastatin (1,729 ) 0.80 0.56-1.04 0.72** 0.57-0.86

Hepatocellular carcinoma atorvastatin ( 11,867) 0.60** 0.51-0.69 0.59** 0.50-0.68
rosuvastatin (2,482 ) 0.51** 0.37-0.66 0.62** 0.50-0.74
simvastatin ( 8,353) 0.71** 0.60-0.84 0.69** 0.56-0.81
lovastatin (499 ) 0.45** 0.13-0.76 0.55** 0.42-0.68
pravastatin (2,402) 0.77* 0.56-0.97 0.82 0.63-1.01
fluvastatin (710) 0.97 0.45-1.46 0.99 0.80-1.18
pitavastatin (1,729 ) 0.72* 0.45-0.99 0.68** 0.51-0.86

Adjusted for dyslipidemia, cardiovascular disease, hypertension, cerebrovascular disease, diabetes mellitus, antihypertensive medication, antidiabetic medication, and lipid-lowering agents (except statin).

* p<0.05, ** p<0.01

Yakhak Hoeji 2024;68:44-55 https://doi.org/10.17480/psk.2024.68.1.44
© 2024 Yakhak Hoeji